FDA, HHS Advisory Board Meeting on a Nonprescription Birth Control Pill

Live Chat

The Food and Drug Administration (FDA) and Department of Health and Human Services hold a public advisory committee meeting of the Nonprescription Drugs Advisory Committee and the Obstetrics, Reproductive and Urologic Drugs Advisory Committee from 9:30 a.m. to 5:30 p.m. ET on May 9.

The committees discuss supplemental new drug application (sNDA) 017031/S-041, for OPILL (norgestrel) Tablet, 0.075 mg, submitted by Laboratoire HRA Pharma. OPILL is proposed for nonprescription use as a once-a-day oral contraceptive to prevent pregnancy.

ntd newsletter icon
Sign up for NTD Daily
What you need to know, summarized in one email.
Stay informed with accurate news you can trust.
By registering for the newsletter, you agree to the Privacy Policy.